Subscribe
kuzma-shutterstock-com-1
Kuzma / Shutterstock.com
1 March 2016Americas

IPR process creates bias, Ethicon says

The Patent Trial and Appeal Board’s (PTAB) process of allowing the same three judges to decide whether to institute an inter partes review (IPR) and on the validity of the patent in question creates legal biases, Ethicon Endo-Surgery has argued.

Already registered?

Login to your account

To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.

Two Weeks Free Trial

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk


More on this story

Americas
CAFC: same judges can rule on IPR petition and patent validity
19 January 2016   The US Court of Appeals for the Federal Circuit has ruled that the same three administrative patent law judges who determine whether to institute an inter partes review can also rule on the validity of the patent at issue.


Editor's picks

Americas
UPC bans Meril Life Sciences from selling infringing heart valve
19 November 2024

Editor's picks

Americas
UPC bans Meril Life Sciences from selling infringing heart valve
19 November 2024

More on this story

Americas
CAFC: same judges can rule on IPR petition and patent validity
19 January 2016   The US Court of Appeals for the Federal Circuit has ruled that the same three administrative patent law judges who determine whether to institute an inter partes review can also rule on the validity of the patent at issue.

More on this story

Americas
CAFC: same judges can rule on IPR petition and patent validity
19 January 2016   The US Court of Appeals for the Federal Circuit has ruled that the same three administrative patent law judges who determine whether to institute an inter partes review can also rule on the validity of the patent at issue.

More features

Gilead awarded $30m over counterfeit HIV drug scheme
EPO invalidates human milk patent after Nestle opposition
Bayer gains exclusive licence for heart drug in Japan
EPO delivers key Novo Nordisk, GSK and Inhibrx rulings
McGuireWoods expands team with ex-Novo Nordisk GC
Paul, Weiss swoops for senior duo from Weil, Gotshal
UPC bans Meril Life Sciences from selling infringing heart valve
SCOTUS denies Alvogen unit's appeal to sell Bausch Xifaxan generic